| Objective To evaluate the efficacy and safety of umbilical cord-mesenchymal stem cells(UCMSCs)in children with acute graft versus host disease(a GVHD)and hemorrhagic cystitis(HC)after allogeneic hematopoietic stem cell transplantation.Methods A total of 15 pediatric patients with refractory a GVHD or HC after allogeneic hematopoietic stem cell transplantation(allo-HSCT),including 13 a GVHD(grade Ⅰ for 2 cases,grade III for 8 cases and grade IV for 5 cases)and 5 HC(grade III for 4 cases and grade IV for 1 case).With a poor outcome after conventional treatment,we gave combined intravenous infusion with UCMSCs.The mean dose of UCMSCs was 3.6(range 1.25-6.0)×108 cells per kg bodyweight and the mean therapeutic times were 5(range 2-21).Then we observed the recovery,recurrence of a GVHD and HC and adverse reactions.Results A total of 13 cases pediatric patients with a GVHD after allo-HSCT were treated with first-line immunosuppressor and CD25 monoclonal antibody,but these conventional treatments were ineffective.After combined treatment with UCMSCs administration,8 patients had a complete response and 5 patients had a partial response.With a poor outcome after hydration and alkalization in 5 HC patients,symptoms disappeared after combined intravenous infusion with UCMSCs.No patients had obvious side effect after infusion with UCMSCs.Conclusion UCMSCs are safe and effective for the combined treatment of children with a GVHD or HC after allogeneic hematopoietic stem cell transplantation. |
PDF Full Text Request